Inovio Pharmaceuticals, Inc. (GBM.F)
| Previous Close | 8.77 |
| Open | 8.67 |
| Bid | 8.49 x N/A |
| Ask | 8.56 x N/A |
| Day's Range | 8.67 - 8.67 |
| 52 Week Range | 3.77 - 12.14 |
| Volume | |
| Avg. Volume | 168 |
| Market Cap | 224.646M |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D., Managing Director and equity research analyst at Stephens, Inc.
- PR Newswire
INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- PR Newswire
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
